Insilico Medicine completes first-in-human dosing of AI-designed non-opioid pain candidate ISM9528
What's the deal? Insilico Medicine, the AI-driven drug discovery company listed on the Hong Kong Stock Exchange, announced on 17 November 2026 that it has completed first-in-human dosing in an exploratory trial of ISM9528, an AI-designed non-opioid candidate for chronic neuropathic pain. The study is an open-label Phase 1 single-ascending-dose trial in healthy adults, run in the United Arab Emirates, evaluating safety, tolerability, pharmacokinetics (how the drug moves through the body) and pharmacodynamics (what the drug does to the body) of the oral candidate.
Why it matters: ISM9528 is being developed as an alternative to opioid painkillers, which carry addiction and overdose risks. It was selected as Insilico's 31st preclinical candidate earlier in 2026 and is one of a wave of generative-AI-designed molecules the company is pushing into the clinic. Completing dosing in the first human study is a key step toward deciding whether to advance ISM9528 into formal Phase 1 development for chronic pain, an area of significant unmet need.
Read more: Insilico Medicine (HKEX announcement via 6ix), 17 November 2026